A longitudinal study of organizational formation, innovation adoption, and dissemination activities within the National Drug Abuse Treatment Clinical Trials Network
- PMID: 20307795
- PMCID: PMC2844868
- DOI: 10.1016/j.jsat.2009.12.008
A longitudinal study of organizational formation, innovation adoption, and dissemination activities within the National Drug Abuse Treatment Clinical Trials Network
Abstract
The National Institute on Drug Abuse established the National Drug Abuse Treatment Clinical Trials Network (CTN) to conduct trials of promising substance abuse treatment interventions in diverse clinical settings and to disseminate results of these trials. This article focuses on three dimensions of CTN's organizational functioning. First, a longitudinal dataset is used to examine CTN's formation as a network of interorganizational interaction among treatment practitioners and researchers. Data indicate strong relationships of interaction and trust, but a decline in problem-centered interorganizational interaction over time. Second, adoption of buprenorphine and motivational incentives among CTN's affiliated community treatment programs (CTPs) is examined over three waves of data. Although adoption is found to increase with CTPs' CTN participation, there is only modest evidence of widespread penetration and implementation. Third, CTPs' pursuit of the CTN's dissemination goals are examined, indicating that such organizational outreach activities are underway and likely to increase innovation diffusion in the future.
Similar articles
-
Partnerships and pathways of dissemination: the National Institute on Drug Abuse-Substance Abuse and Mental Health Services Administration Blending Initiative in the Clinical Trials Network.J Subst Abuse Treat. 2010 Jun;38 Suppl 1(Suppl 1):S31-43. doi: 10.1016/j.jsat.2009.12.013. J Subst Abuse Treat. 2010. PMID: 20307793 Free PMC article.
-
Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.J Subst Abuse Treat. 2009 Oct;37(3):307-12. doi: 10.1016/j.jsat.2008.12.004. Epub 2009 Jul 3. J Subst Abuse Treat. 2009. PMID: 19577406 Free PMC article.
-
The first decade of the National Drug Abuse Treatment Clinical Trials Network: bridging the gap between research and practice to improve drug abuse treatment.J Subst Abuse Treat. 2010 Jun;38 Suppl 1(Suppl 1):S4-13. doi: 10.1016/j.jsat.2010.01.011. J Subst Abuse Treat. 2010. PMID: 20307794 Free PMC article.
-
Recent advances in the dissemination of contingency management techniques: clinical and research perspectives.J Subst Abuse Treat. 2002 Sep;23(2):81-6. doi: 10.1016/s0740-5472(02)00251-9. J Subst Abuse Treat. 2002. PMID: 12220605 Review.
-
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".Addict Sci Clin Pract. 2021 Mar 6;16(1):15. doi: 10.1186/s13722-021-00223-z. Addict Sci Clin Pract. 2021. PMID: 33676577 Free PMC article. Review.
Cited by
-
If health organisations and staff engage in research, does healthcare improve? Strengthening the evidence base through systematic reviews.Health Res Policy Syst. 2024 Aug 19;22(1):113. doi: 10.1186/s12961-024-01187-7. Health Res Policy Syst. 2024. PMID: 39160553 Free PMC article.
-
Improving treatment for opioid dependence: a perspective from the Ohio Valley node of the NIDA Clinical Trials Network.Prog Community Health Partnersh. 2014 Spring;8(1):99-107. doi: 10.1353/cpr.2014.0002. Prog Community Health Partnersh. 2014. PMID: 24859107 Free PMC article.
-
Quality of clinical supervision and counselor emotional exhaustion: the potential mediating roles of organizational and occupational commitment.J Subst Abuse Treat. 2013 May-Jun;44(5):528-33. doi: 10.1016/j.jsat.2012.12.003. Epub 2013 Jan 10. J Subst Abuse Treat. 2013. PMID: 23312873 Free PMC article.
-
Clinicians' perceptions of implementation extensiveness of 100% tobacco free practices: a longitudinal study of New York state.J Behav Health Serv Res. 2014 Jan;41(1):50-63. doi: 10.1007/s11414-013-9319-1. J Behav Health Serv Res. 2014. PMID: 23430285 Free PMC article.
-
Sustainment of Contingency Management within Opioid Treatment Programs: COVID-Related Barriers and Innovative Workflow Adaptations.Drug Alcohol Depend Rep. 2021 Dec;1:100003. doi: 10.1016/j.dadr.2021.100003. Epub 2021 Nov 22. Drug Alcohol Depend Rep. 2021. PMID: 36277301 Free PMC article.
References
-
- Agrawal M, Grady C, Fairclaough DL, Meropol NJ, Maynard K, Emanuel EJ. Patients’ decision-making process regarding participation in phase I oncology research. Journal of Clinical Oncology. 2006;24:4479–4484. - PubMed
-
- Brown B. Reducing impediments to technology transfer in drug abuse. In: Backer TE, David SL, Soucy G, editors. Reviewing the behavioral science knowledge base on technology transfer. 1995. pp. 169–185. NIDA Research Monograph155. - PubMed